Sympathetic renal denervation: randomized trials and clinical practice

The objective of this study is to evaluate the efficacy and safety of renal denervation in patients with resistant hypertension and other cardiovascular diseases. The method of renal denervation is based on radiofrequencymediated destruction of renal sympathetic nerves going within the renal artery wall. Initial clinical success of renal denervation in Symplicity I and Symplicity II trials was replaced by more cautious approach after results of Symplicity III. In this study the renal denervation resulted in reduction of blood pressure after procedure but failed to prove the significant difference between main group (renal denervation) and group with imitation of denervation (sham-procedure), which was the clinical efficacy endpoint. The safety endpoint was the incidence of 30‑day complications (vascular complications at puncture site, occurrence of renal artery stenosis, progression of renal insufficiency). There was no difference in the rate of complications between denervation group and shamprocedure group. Subgroup analysis (according to patients’ clinical and demographic characteristics) demonstrated the clinical efficacy of renal denervations in patients younger than 65 years and in Caucasian patients. There are also clinical data, indicating clinical efficacy of renal denervation in the treatment of cardiovascular diseases, associated with high activity of sympathetic nervous system: chronic heart failure, sleep apnea, atrial fibrillation, ventricular arrhythmias.

resistant hypertension, renal denervation, Symplicity, chronic heart failure, sleep apnea, arrhythmias

1. Volobuev AN, Koshev VI, Petrov ES. Biophysical principles of hemodynamics. New York: Nova Science Publishers, Inc.; 2010. 215 p.

2. Evelyn KA, Singh MM, Chapman WP, Perera GA, Thaler H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med. 1960;28:188–221.

3. Takahashi H, Iyoda I, Yamasaki H, Takeda K, Okajima H, Sasaki S et al. Retardation of the development of hypertension in DOCA-salt rats by renal denervation. Jpn Circ J. 1984;48 (6):567–574.

4. Iversen BM, Kvam FI, Matre K, Ofstad J. Resetting of renal blood autoregulation during acute blood pressure reduction in hypertensive rats. Am J Physiol. 1998;275(2 Pt.2):R343‑R349.

5. OcHagan KP, Thomas GD, Zambraski EJ. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens. 1990;3(1):62–64.

6. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361(9):932–34.

7. Krum H, Schlaich M, Whitbourn R, Sobotka PA, SadowskiJ, Bartus K et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275–81.

8. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA; Symplicity HTN‑2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN‑2 randomized, controlled trial. Circulation. 2012;126 (25):2976–2982.

9. Bhatt DL, Kandzari DE, O’Neill WW, D’AgostinoR, FlackJM, Katzen BT et al. SYMPLICITY HTN‑3 Investigators. Acontrolled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. doi: 10.1056/NEJMoa1402670.

10. Witkowski AI, Prejbisz A, Florczak E, Kądziela J, Śliwiński P, Bieleń P et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension.2011;58 (4):559–65. doi: 10.1161/HYPERTENSIONAHA.111.173799.

11. Taborsky M. The effect of renal denervation in patients with advanced heart failure: The OLOMOUC I study. Presented at: European Society of Cardiology Congress; August 27, 2012; Munich, Germany.

12. Pokushalov E1, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–70. doi: 10.1016/j.jacc.2012.05.036. Epub 2012 Sep 5.

13. Покушалов Е.А., Романов А.Б., Артеменко С.Н. Циркулярные изоляции легочных вен в сочетании с денервацией почечных артерий у пациентов с фибрилляцией предсердий и резистентной артериальной гипертензией. Вестник аритмологии. 2013;71:19–25. [Pokushalov EA, Romanov AB, Artemenko SN. Circular pulmonary vein isolation in combination with renal artery denervation in patients with atrial fibrillation and resistant arterial hypertension. Vestnik aritmologii. 2013;71:19–25. In Russian].

14. Tsioufis K. Ventricular arrhythmia episodes may decrease after renal denervation in resistant hypertensive patients. ACC meeting. 2013;15:58.